Vivos Therapeutics, Inc. (VVOS)
Pre-market:
| Previous close | 2.3900 |
| Open | 2.3900 |
| Bid | 2.1100 x 100 |
| Ask | 2.2200 x 100 |
| Day's range | 2.1700 - 2.4301 |
| 52-week range | 2.1700 - 48.7900 |
| Volume | |
| Avg. volume | 175,562 |
| Market cap | 6.531M |
| Beta (5Y monthly) | 7.99 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Insider Monkey
Vivos Therapeutics, Inc. (NASDAQ:VVOS) Q4 2023 Earnings Call Transcript
Vivos Therapeutics, Inc. (NASDAQ:VVOS) Q4 2023 Earnings Call Transcript March 28, 2024 Vivos Therapeutics, Inc. misses on earnings expectations. Reported EPS is $-3.05 EPS, expectations were $-1.9. VVOS isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good day, everyone, and […]
- Simply Wall St.
Vivos Therapeutics Full Year 2023 Earnings: Misses Expectations
Vivos Therapeutics ( NASDAQ:VVOS ) Full Year 2023 Results Key Financial Results Revenue: US$13.8m (down 14% from FY...
- Reuters
UPDATE 2-US FDA clears Vivos Therapeutics' oral device for sleep apnea
Vivos Therapeutics said on Wednesday the U.S. health regulator has cleared its oral device for severe obstructive sleep apnea (OSA), leading a massive rally in the company's shares before the bell. Shares of the medical device maker more than doubled to $9.12 in premarket trading. The clearance is the first ever for an oral appliance, along with a mode of respiratory ventilation or exercise training program for the muscles around face, mouth and tongue, to treat moderate and severe OSA in adults.
